Author

S.-Y. Cheng

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2

Frequent Co-Authors

B. Hu· 2 shared X. Song· 2 shared A. A. Mujeeb· 1 shared A. Comba· 1 shared A. Goenka· 1 shared A. Mauser· 1 shared A. Taher· 1 shared B. Erdogdu· 1 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Epigenetic reprogramming of autophagy leads to uncovering a novel therapeutic target for mutant IDH1 astrocytomas

F. J. Nunez, K. Banerjee, A. A. Mujeeb, A. Mauser, C. E. Tronrud, Z. Zhu, S. Raghuram, M. R. Sheth, J. A. Pena Agudelo, J. Zelaya, A. Taher, P. Kadiyala, S. V. Carney, M. B. Garcia-Fabiani, A. Comba, , M. Castro

This study identifies autophagy as a critical survival pathway in mIDH1 gliomas and shows that inhibiting autophagy enhances radiosensitivity and tumor regression in preclinical models.

bioRxiv · Mar 8, 2024 · PreprintCancer Biology

Thyroid Hormone Suppresses Medulloblastoma Progression Through Promoting Terminal Differentiation of Tumor Cells

Z. Yang, Y. Yang, S. A. Valdes-Rives, Q. Liu, Y. Li, J. Tan, Y. Tan, C. A. Koch, Y. Rong, S. R. Houser, S. Wei, K. Cai, S.-y. Cheng, T. Curran, R. Wechsler-Reya

This study shows thyroid hormone promotes differentiation of medulloblastoma cells, reducing tumor growth by reversing EZH2-mediated repression of NeuroD1.

bioRxiv · Feb 13, 2024Cancer Biology

Repurposing clemastine to target glioblastoma cell stemness

M. A. Sun, R. Yang, H. Liu, W. Wang, X. Song, B. Hu, N. Reynolds, K. Roso, L. H. Chen, P. K. Greer, S. T. Keir, R. E. McLendon, S.-Y. Cheng, D. D. Bigner, D. M. Ashley, , Y. He

This study shows clemastine, an antihistamine, reduces glioblastoma stemness by targeting EBP, a cholesterol pathway enzyme, and promotes differentiation of oligodendrocyte progenitor cells.

bioRxiv · Nov 5, 2022 · PreprintCancer Biology

Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug resistant gliomas

D. M. Tiek, B. Erdogdu, R. Razaghi, L. Jin, N. Sadowski, C. Alamillo-Ferrer, J. R. Hogg, B. R. Haddad, D. H. Drewry, C. I. Wells, J. E. Pickett, X. Song, A. Goenka, B. Hu, S. L. Goldlust, , R. B. Riggins

This study identifies guanine mutations in TMZ-resistant gliomas that disrupt G4 structures and splice sites, creating vulnerabilities targeted by G4 stabilizers and splicing inhibitors.

bioRxiv · Nov 21, 2021Cancer Biology